Treatment of secondary hyperparathyroidism in ESRD: A 2-year, single-center crossover study

Kidney International

Volumn 78, Issue SUPPL. 117, 2010, Pages

  Mittman, Neal ^a   Desiraju, Brinda ^a   Meyer, Kevin B ^a   Chattopadhyay, Jyoti ^a   Avram, Morrell M ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

Author keywords

calcitriol; hemodialysis; paricalcitol; secondary hyperparathyroidism; vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; 1 ALPHA HYDROXYERGOCALCIFEROL; 1 ALPHA-HYDROXYERGOCALCIFEROL; ERGOCALCIFEROL;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; URBAN AREA; BLOOD; CALCINOSIS; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY;

AGED; CALCINOSIS; CALCITRIOL; CALCIUM; CROSS-OVER STUDIES; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 77955141586     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.191     Document Type: Article

References (34)

1. Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 2007; 333: 201-207.
2. Slatopolsky E, Lopez-Hilker Delmez J, Dusso A. The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int 1986; 29: S41-S47.
3. Friedman EA. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int 2005; 67(Suppl 95): S1-S7.
4. Michael M, Garcia D. Secondary hyperparathyroidism in chronic kidney disease: clinical consequences and challenges. Nephrol Nurs J 2004; 31: 185-194.
5. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
6. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23: 369-379.
7. Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008; 29: 433-452.
8. Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol 2004; 24: 456-459.
9. Salusky IB. Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol 2005; 20: 393-398.
10. Cheng S, Coyne D. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. Expert Opin Pharmacother 2006; 7: 617-621.
11. Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999; 21: 432-441.
12. Cozzolino M, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother 2008; 9: 947-954.
13. Slatopolsky E, Finch J, Ritter C et al. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 1998; 32: S40-S47.
14. Slatopolsky E, Brown AJ. Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif 2002; 20: 109-112.
15. Mittman N, Khanna R, Rani S et al. Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single center crossover study. Kidney Int 2006; 70: S64-S67.
16. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
17. Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19: 1174-1181.
18. Llach FL, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38(suppl 5): S45-S50.
19. Seeherunvong W, Nwobi O, Abitbol CL et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006; 21: 1434-1439.
20. Sprague SM, Lerma E, McCormmick D et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-S56.
21. Joist HE, Ahya SN, Giles K et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol 2006; 65: 335-341.
22. Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106.
23. Capuano A, Serio V, Pota A et al. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 2009; 22: 59-68.
24. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
25. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004; 17: 209-216.
26. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium X phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
27. Raggi P. Electron beam tomography to image cardiovascular calcifications in hemodialysis patients. J Nephrol 2002; 15(Suppl 6): S77-S81.
28. Avram MM, Feinfeld DA, Huatuco AH. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 1978; 298: 1000-1003.
29. Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 2003; 26: 1136-1142.
30. Zanos S, Mitsopoulos E, Sakellariou G. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients. Ren Fail 2005; 27: 163-169.
31. Gonzalez EA, Martin KJ. Renal osteodystrophy: pathogenesis and management. Nephrol Dial Transplant 1995; 3: 13-21.
32. Massry SG, Goldstein DA. Role of parathyroid hormone in uremic toxicity. Kidney Int 1978; 8: S39-S42.
33. Ha SK, Park CH, Seo JK et al. Studies on bone markers and bone mineral density in patients with chronic renal failure. Yonsei Med J 1996; 37: 350-356.
34. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663.